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Data of the patients with systolic heart failure before and after vitamin D
supplementation
Before Vitamin D
Supplementation
After Vitamin D
Supplementation P Value
25-OH vitamin D
level (ng/ml)
11.66  5.12 40.720  14.74 <0.001
6- MWT(m) 461.0  79.97 559.25  71.96 <0.001
LVEF (%) 31.70  3.40 35.50  4.00 <0.001
LVDd (mm) 60.00  9.67 57.95  9.21 <0.001
LVSd (mm) 50.40  6.40 48.10  6.18 <0.001
LA (mm) 42.5  6.50 42.40  6.60 0.818
RA (mm) 38.2  6.06 38.4  6.04 0.729
RV (mm) 37.8  5.81 38.1  5.83 0.670
Calcium (mg/dl) 9.46  0.45 9.64  0.50 0.330
Phosphate (mg/dl) 3.480.97 3.52  0.88 0.681
Sodium (mmol/l) 138.45  3.42 137.75  3.71 0.283
PTH (pg/ml) 62.95  40.40 46.45  32.24 0.120
ALT (U/l) 20.45  9.26 22.15  10.91 0.191
6-MWT indicates 6 minute walk test; LVEF, left ventricle ejection fraction; LVDd, left ventricle
end diastolic diameter; LVSd, left ventricle end systolic diameter; LA, left atrium; RA, right
atrium; RV, right ventricle; PTH, parathyroid hormone; ALT,alanine amotranspherase.
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Effects of Levosimendan and Dobutamine on Systolic Time Intervals in Patients
with Acute Decompensated Heart Failure
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Fezan Mutlu, Taner Ulus
Eskisehir Osmangazi University, Eskisehir
Purpose: Levosimendan has been shown to have a better hemodynamic proﬁle over
dobutamine in increasing cardiac output and reducing pulmonary wedge pressure in
patients with acute decompensated heart failure (HF). Data comparing the effect of
levosimendan with dobutamine on systolic time intervals is lacking. Therefore, the
aim of this study was to evaluate the effects of levosimendan and dobutamine on
systolic time intervals.
Methods: Fifty patients with NYHA class III-IV decompensated HF requiring
inotropic support, LVEF <35% and in sinus rhythm were randomized (in a 1:1
design) to levosimendan (n¼25) or dobutamine (n¼25). Both inotropic agents were
administered as a continuous 24-h infusion (levosimendan at a dose of 0.2 mgr/kg/min
with a preceding bolus dose of 12 mgr/kg and dobutamine at a dose of 10 mgr/kg/min
without a bolus dose). All patients underwent echocardiographic evaluation before
and at the end of inotropic infusion. LVEF, heart rate-corrected electromechanical
systole (QS2i), pre-ejection period (PEP) and left ventricular ejection time (LVET)
were measured.
Results: There was no signiﬁcant difference in baseline clinical characteristics and
laboratory parameters between levosimendan and dobutamine groups. As compared
with their baseline values, LVEF and LVET signiﬁcantly increased at the end of both
levosimendan and dobutamine infusions with a similar extent in both groups (table).
Levosimendan signiﬁcantly shortened QS2i and PEP. Dobutamine shortened PEP, but
showed no effect on QS2i.
Conclusıons: This study suggests that both levosimendan and dobutamine are almost
equally effective in increasing LVET and in shortening PEP. However, levosimendan
appears to have additional advantage over dobutamine in shortening QS2i, indicating
a fairly strong positive inotropic effect.Systolic time intervals during inotropic therapy
Before
Dobutamine
After
Dobutamine p
Before
Levosimendan
After
Levosimendan p
LVEF, % 27.94.6 30.84.7 0.0001 26.05.5 30.65.4 0.0001
QS2i,
ms
54324 53627 0.112 52338 50938 0.003
PEP,
ms
11716 10618 0.0001 12022 10921 0.001
LVET,
ms
24238 25238 0.0001 23028 24025 0.039
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Background: Warfarin use and associated outcomes in patients with chronic heart
failure (HF) have not been well described previously. We hypothesized that warfarin
is associated with lower risks of cardiovascular mortality in patients with sinus
rhythm, atrial ﬁbrillation and pacemaker rhythm.
Methods: We examined the outcomes in patients who were followed –up between
January 2003 and April 2011 in the out-patient clinic due to chronic HF. 671 HF
patients were enrolled into the study group (427 male, 244 female, mean age, 64  13
years; mean ejection fraction, 27  12%, mean NYHA 2.80.5, 62% with coronary
artery disease). 445 patients had sinus rhythm, 165 patients had atrial ﬁbrillation and
61 patients had pacemaker rhythm.
Results: Two hundred -ﬁfty three patients (38%) died due to cardiovascular reasons.
210 (31 %) patients were on warfarin treatment. However 27 patients (63%) who were
not taken warfarin died, 39 patients (%32) who were taken warfarin died in atrial
ﬁbrillation (p<0.001) due to cardiovascular reasons during follow-up. Although 149
patients (40%) who were not on warfarin treatment died and 18 patients (24 %) who
were on warfarin treatment died in sinus rhythm due to cardiovascular reasons during
follow-up (p¼0.006). We did not ﬁnd any statistical difference between patients with
warfarin user and patients who were not user in patients with pacemaker rhythm.
Conclusıon: It seemed patients who were taken warfarin had better outcomes in
patients with atrial ﬁbrillation and in patients with sinus rhythm in chronic HF.
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Heart failure (HF) is a common disease worldwide. On the other hand, regular
physical activity is beneﬁcial in terms of outcomes. In this study, parameters which
inﬂuence regular activity were investigated.
100 consecutive outpatients (age 6513 years, 54 males, 46 females) with stable
systolic heart failure (3110% ejection fraction) were enrolled. All patients were
asked for engagement with regular physical activity, and evaluated with Beck
depression inventory (BDI).
Results: 41 out of 100 patients stated that they engage regular physical activity with
a median of 3 days per week (ranging from 1-7 days/week). In the univariate analysis,
absence of regular physical activity was associated with female gender, lower ejection
fraction (EF), higher NYHA functional class, nonischemic etiology, presence of
therapy with spironolactone, higher BNP, BUN, longer duration of HF, lower plasma
sodium, higher tricuspid annular excursion (Table 1). Patients were classiﬁed into
two as those with presence of at least mild depression (BDI score 14) versus
those without depression. It was found that at least mild form of depression (BDI 14)
was found in 36.6% of patients having regular physical activity whereas, depression
was present in 88.1% of patients not having regular physical activity. Of note,
severe depression (BDI 29) was present in 7.3% and 49.2% respectively. Beck
depression score was able to predict absence of engagement in regular physical
activity in patients with HF (AUC¼0.827, p<0.001). In the stepwise regression
analysis, it was found that female gender (p¼0.010, ExpB¼4.251, 95%CI:1.417-
12.751), having at least mild depression by BDI (p¼0.0.10, ExpB¼4.639 95%
CI:1.451-14.829) and EF (p¼0.017, ExpB¼0.928, 95% CI:0.873-0.986) were found
to be independent predictors of absence of regular physical activity in stable outpa-
tients with systolic HF.
Conclusıon: Depression could potentially inﬂuence engagement in regular physical
activity in outpatients with systolic HF.l 62/18/Suppl C j October 26–29, 2013 j TSC Abstracts/POSTERS
